Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15931904 | 0.86 | THRB (0.51) | THRBRAB9ASMN1; SMN2POLBP4HTM | |
| SCHEMBL8283554 | 0.85 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2POLBNPC1FFAR1 | |
| SCHEMBL17967233 | 0.84 | DAO (0.48) | RAB9ASMN1; SMN2POLBENPP2NPC1 | |
| SCHEMBL17309743 | 0.84 | HCAR2 (0.49) | RAB9ASMN1; SMN2POLBNPC1NR3C2 | |
| SCHEMBL15931682 | 0.81 | THRB (0.47) | THRBRAB9ASMN1; SMN2POLBNPC1 | |
| SCHEMBL31643942 | 0.76 | ALDH1A1 (0.42) | RAB9ASMN1; SMN2POLBNPC1 | |
| SCHEMBL6821314 | 0.76 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2POLBNPC1 | |
| SCHEMBL5449783 | 0.76 | DAO (0.48) | THRBRAB9ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL15931975 | 0.76 | NPC1 (0.60) | RAB9ASMN1; SMN2POLBNPC1L3MBTL1 | |
| SCHEMBL15932310 | 0.76 | HDAC6 (0.52) | RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428061-B2 | Autotaxin inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3253748-B1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124938-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | THRB 1667/4885RAB9A 810/4885SMN1; SMN2 3625/4885 |
| US-10428061-B2 | Autotaxin inhibitors | ENPP2, ATXN10, RNASE1 | THRB 1579/4885RAB9A 916/4885SMN1; SMN2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.